Jane Street Group LLC Sells 20,543 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Jane Street Group LLC lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 33.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,265 shares of the specialty pharmaceutical company’s stock after selling 20,543 shares during the period. Jane Street Group LLC owned 0.13% of Collegium Pharmaceutical worth $1,182,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in COLL. New Age Alpha Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $40,000. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after buying an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $230,000.

Insider Activity

In other news, CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the transaction, the executive vice president now directly owns 108,137 shares in the company, valued at approximately $3,081,904.50. The trade was a 19.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Stock Up 0.4%

NASDAQ:COLL opened at $29.96 on Wednesday. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a market cap of $962.67 million, a price-to-earnings ratio of 12.91 and a beta of 0.63. The stock has a fifty day simple moving average of $28.15 and a 200-day simple moving average of $29.80. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the firm posted $1.45 EPS. The business’s revenue was up 22.7% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on COLL shares. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.